Results 241 to 250 of about 325,395 (379)

A pseudopeptide that is a potent cholecystokinin agonist in the peripheral system is able to inhibit the dopamine-like effects of cholecystokinin in the striatum.

open access: hybrid, 1988
Christiane Mendre   +7 more
openalex   +1 more source

A Scalable Population Code for Time in the Striatum

open access: yesCurrent Biology, 2015
Gustavo B. M. Mello   +2 more
semanticscholar   +1 more source

Early‐Onset Movement Disorder Syndrome Caused by Biallelic Variants in PDE1B Encoding Phosphodiesterase 1B

open access: yesMovement Disorders, EarlyView.
Abstract Background Breakdown of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in basal ganglia cells through hydrolysis of diesteric bonds, primarily by PDE10A and PDE1B, is essential for normal human movement. While biallelic loss‐of‐function variants in PDE10A are known to cause hyperkinetic movement disorders, the ...
Tomer Poleg   +21 more
wiley   +1 more source

A Convergent Pathway for Stimulation‐Induced Dyskinesia Following Deep Brain Stimulation

open access: yesMovement Disorders, EarlyView.
Abstract Background Stimulation‐induced dyskinesias (SID) from deep brain stimulation (DBS) of the subthalamic nucleus (STN) and globus pallidus internus (GPi) are uncommon; however, they are increasingly recognized. Once considered transient and indicative of effective neuromodulation, SID are now seen as potential therapy‐limiting side effects, akin ...
Joshua K. Wong   +4 more
wiley   +1 more source

Striatal cue-reactivity and neurotransmitter function in gambling disorder. [PDF]

open access: yesJ Behav Addict
Bellmunt-Gil A   +7 more
europepmc   +1 more source

Disease‐Modifying Trials in Treated Parkinson's Disease: “Stable Treated” Does Not Equate with Biological Stability

open access: yesMovement Disorders, EarlyView.
Abstract Traditionally, clinical trials of putative disease‐modifying therapies in Parkinson's disease have enrolled untreated patients at the earliest clinical stages of their disease. Due to a number of challenges inherent with this approach, there has been a recent move to a different study design, enrolling patients who are already taking “stable ...
M. Maral Mouradian   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy